Anti-CD7 and anti-CD19 chimeric antigen receptor T cell therapy

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-CD7 and anti-CD19 chimeric antigen receptor T cell therapy
Drug Alias NameAnti-CD7 and anti-CD19 chimeric antigen receptor T cell therapy - Gracell BiothechnologiesGC-197
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Universal CAR-TCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Dual-target CAR-T cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19T-cell antigen CD7 inhibitors
TargetsB-lymphocyte antigen CD19T-cell antigen CD7
Therapy Area/IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesGracell Biotechnologies (Shanghai) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGracell Biotechnologies (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A